Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome
The Randomized Controlled Trial (RCT) on the Vaporized Perfluorocarbon (PFC) Inhalation Treatment of Acute Respiratory Distress Syndrome With the Invasive Mechanical Ventilation（IMV）
Sponsor: 309th Hospital of Chinese People's Liberation Army
This PHASE2 trial investigates Acute Lung Injury and Respiratory Distress Syndrome, Adult and is currently ongoing. 309th Hospital of Chinese People's Liberation Army leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 309th Hospital of Chinese People's Liberation Army
- Air Force General Hospital of the PLA
- Beijing Shijitan Hospital, Capital Medical University
- Chinese PLA General Hospital
- First Hospitals affiliated to the China PLA General Hospital
- General Hospital of Chinese Armed Police Forces
- The 306 Hospital of People's Liberation Army
- The Second Artillery General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .